FDA advisory committee to consider CV studies for diabetes drugs

FDA will ask an advisory committee this week to consider whether cardiovascular outcomes trial requirements for diabetes drugs should be diminished or discarded, according to draft questions released ahead of the Oct. 24-25 meeting.